Biotech Values

[DewDiligence]

The various means of circumventing the 180-day exclusivity of Teva/Amphastar will likely turn out to be moot. If a final decision on the Lovenox patent appeal comes in the next couple of months and thereby starts the 180-day clock, the probability is high that the 180 days will run out or nearly run out before any company gets FDA approval.